Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Schering Zetia Has 50% Combo Use; Statin Of Choice Is Lipitor 

Executive Summary

Prescriptions for Merck/Schering-Plough's Zetia during the drug's first six weeks on the market have been split equally between monotherapy and combination use with other cholesterol-reduction products

You may also be interested in...



Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says

Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels

Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says

Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels

Merck/Schering Zetia Early Use Is In High-Risk Patients; New Rx Share At 5%

Schering-Plough is seeing most of the early use of Zetia in either high-risk or statin-intolerant patients, Global Pharmaceuticals President Carrie Cox told investors during a quarterly earnings call Oct. 22

Related Content

UsernamePublicRestriction

Register

PS041207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel